Title:
ANTIBODIES DERIVED ROM ANTI ED-B L19 AND TARGETING TUMOR VASCULATURE
Document Type and Number:
WIPO Patent Application WO2003076469
Kind Code:
A9
Abstract:
The present invention relates to selectively targeting tumoral vasculature in vivo using a human recombinant scFv, L19, to the angiogenesis marker ED-B domain of fibronectin. In preferred embodiments, a complete human IgG1 is employed having the variable regions of L19. In other embodiments is employed a mini-immunoglobulin generated by fusing the scFv L19 to the constant CH4 domain of a secretory IgE isoform that naturally contains a cysteine in its COOH terminal and which forms a covalently linked dimer. Different in vivo behaviour of the antibody formats is exploitable for different diagnostic and/or therapeutic purposes, depending on clinical needs and disease. The antibody molecules may be labelled as described.
More Like This:
Inventors:
BORSI LAURA (IT)
CARNEMOLLA BARBARA (IT)
BALZA ENRICA (IT)
CASTELLANI PATRIZIA (IT)
ZARDI LUCIANO (IT)
FRIEBE MATTHIAS (DE)
HILGER CHRISTOPH-STEPHAN (DE)
CARNEMOLLA BARBARA (IT)
BALZA ENRICA (IT)
CASTELLANI PATRIZIA (IT)
ZARDI LUCIANO (IT)
FRIEBE MATTHIAS (DE)
HILGER CHRISTOPH-STEPHAN (DE)
Application Number:
PCT/IB2003/001458
Publication Date:
September 29, 2005
Filing Date:
March 11, 2003
Export Citation:
Assignee:
PHILOGEN SPA (IT)
SCHERING AG (DE)
BORSI LAURA (IT)
CARNEMOLLA BARBARA (IT)
BALZA ENRICA (IT)
CASTELLANI PATRIZIA (IT)
ZARDI LUCIANO (IT)
FRIEBE MATTHIAS (DE)
HILGER CHRISTOPH-STEPHAN (DE)
SCHERING AG (DE)
BORSI LAURA (IT)
CARNEMOLLA BARBARA (IT)
BALZA ENRICA (IT)
CASTELLANI PATRIZIA (IT)
ZARDI LUCIANO (IT)
FRIEBE MATTHIAS (DE)
HILGER CHRISTOPH-STEPHAN (DE)
International Classes:
A61K38/00; A61K39/395; A61K51/10; A61P9/00; A61P35/00; A61P43/00; C07K16/18; C07K16/44; C07K19/00; C12N15/09; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/13; C12P21/00; (IPC1-7): C07K16/46; C07K16/18; A61K51/10; G01N33/68; C12N1/21; C12N15/13; A61K39/395; A61P9/00; A61P35/00
Download PDF: